In the USA, a cure for COVID-19 is now available to everyone: how it works

Diana Gumas has gone to great lengths to protect her 86-year-old mother with leukemia from COVID-19. The whole family adhered to the quarantine regime and reduced her social circle to a minimum. But in the end, the woman still fell ill, and then the family resorted to unusual treatment, the newspaper said. Voice of America.

Photo: Shutterstock

In January of this year, they learned that Diana's sister had tested positive for COVID-19. A day later, my mother also confirmed a coronavirus infection.

“I already told them what to do if I don’t survive,” said Barbara Gumas.

“Yes, it's true, and it's terrible. Although she thought that she would not be able to overcome the disease, fortunately, everything was mild for her. This is a real miracle,” Diana the Rock.

Miracle they call the treatment "Bamlanivimab" with monoclonal antibodies to coronavirus and a cocktail of antibodies "Regeneron", which includes casevirimab and indevimab.

A few months before Barbara got sick, an emergency authorization was issued in the United States to use these drugs for people over 12 years old.

“I knew that President Donald Trump received this cocktail of antibodies when he had COVID-19. But I didn’t know that these medicines were available to ordinary people,” Diana noted. — My colleagues told me how to apply online. Within two days, my mother received permission and was given the drug.”

The antibody cocktail is now available for free. One of the largest centers in Maryland is located in Baltimore.

On the subject: The vaccine vs natural immunity: antibodies to differ COVID-19 and which effectively

In the course of clinical trials of the drug, it was found that after the introduction of the cocktail, the disease proceeds in a mild form, which significantly reduces the number of hospitalizations and deaths.

“Both drugs showed a positive effect. In the clinical trial, patients who received the drug were followed for 29 days and compared with a placebo group, says Sofia Purekal, director of the Maryland infusion center. “The latter, unlike those who received a cocktail of antibodies, sought help from doctors and ended up in emergency departments.”

“Patients with leukemia and immunodeficiency - their bodies are not able to produce antibodies on their own. But they are only one of the groups of people who have benefited from this treatment, says Zeeshan Siddiqui, a physician at Johns Hopkins Medical Center. - Chronic diseases, cardiovascular diseases, lung disease, hypertension, diabetes and obesity - people with these diseases are at high risk of developing severe COVID-19. They are the first to get access to this treatment.”

You can get vaccinated only 90 days after drug administration.

To learn more about the antibody cocktail and apply for an authorization to use, please visit link.

What is this drug

“Monoclonal antibodies are proteins made in the laboratory that mimic the immune system’s ability to fight harmful antigens, such as viruses. Bamlanivimab is a monoclonal antibody that specifically targets the SARS-CoV-2 spike protein, designed to block the virus from attaching to and entering human cells,” the FDA said in a statement.

“The FDA's emergency authorization of bamlanivimab provides healthcare providers on the front lines of the pandemic with another potential tool to treat patients with COVID-19,” said Patricia Cavazzoni, acting director of the FDA's Center for Drug Evaluation and Research. “We will continue to evaluate new data on the safety and effectiveness of bamlanivimab as they become available.”

The department's approval was based on a study published in October in the New England Journal of Medicine. It says treatment reduces the risk of hospitalization and alleviates some symptoms in a small number of patients with mild to moderate cases of COVID-19.

You may be interested in: top New York news, stories of our immigrants and helpful tips about life in the Big Apple - read it all on ForumDaily New York

The phase 2 trial included 452 patients, some receiving treatment and others receiving placebo. Only 1,6% of treated patients had symptoms progressing enough to require hospitalization or emergency department care. For patients receiving placebo, the hospitalization rate was 6,3%.

Lilly announced that it has entered into a $ 375 million deal with the government to supply 300 vials of the drug, pending an EUA (Emergency Use Authorization), to be delivered within two months. Lilly applied to participate in the EUA in October.

“Lilly will immediately begin supplying bamlanivimab to national distributor AmerisourceBergen, which will distribute it in accordance with the U.S. government distribution program,” the company said in a statement.

Read also on ForumDaily:

NYT: United States will fail to achieve herd immunity to coronavirus

Women massively complain about irregularities in the cycle after vaccination against COVID-19: is it dangerous

The new COVID-19 strain can be recognized by voice: what to look for

More than 5 million US residents did not come for the second COVID-19 vaccination

Do you want more important and interesting news about life in the USA and immigration to America? — support us donate! Also subscribe to our page Facebook. Select the “Priority in display” option and read us first. Also, don't forget to subscribe to our РєР ° РЅР ° Р »РІ Telegram  and Instagram- there is a lot of interesting things there. And join thousands of readers ForumDaily New York — there you will find a lot of interesting and positive information about life in the metropolis.